Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma

NCT ID: NCT05216029

Last Updated: 2026-01-07

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-01
• Study Completion Date: 2027-02-02

Brief Summary

This clinical trial investigates whether measuring and presenting information about a patient's cancer treatment to them, their doctor, and their radiologist using a tool called an "oncology dashboard" may help patients understand the disease better and help the patient's medical team manage their care more efficiently. The oncology dashboard tool may help patients understand the disease better and may help improve the efficiency of their medical care.

Detailed Description

PRIMARY OBJECTIVE:

I. To compare the changes in oncology workflow times from baseline to follow up visits between intervention (follow-up visit with oncology dashboard tool) and control (follow-up visit without oncology dashboard tool) groups.

SECONDARY OBJECTIVES:

I. To compare the changes in radiology workflow times from baseline to follow up visits between intervention (follow-up visit with oncology dashboard tool) and control (follow-up visit without oncology dashboard tool) groups.

II. Assess and compare the proportion of patients who correctly indicate the changes in tumor size while on therapy at the baseline and at the follow-up visit (with the oncology dashboard tool).

IIa. Compare the change in proportion of patients who correctly indicate the changes in tumor size while on therapy from baseline to follow-up visit between intervention and control groups.

III. Assess the patient's satisfaction with physician communication during the clinic visit and with the current treatment plan at each visit for each group.

IV. Assess changes in the radiology report quality with the following measures (all changes will be compared between intervention and control groups):

IVa. Whether or not the current study was compared to the imaging study that was performed at the start of current therapy.

IVb. The number of time points reviewed by the radiologist. IVc. The time interval between the earliest study reviewed and the current study.

IVd. Percentage of target lesions measured and listed in the radiology report. V. In patients who have stable disease or mildly progressive disease at the time of the baseline assessment, assess the impact of patient understand on the decision to continue and discontinue therapy.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.

GROUP II: Patients receive standard of care.

Conditions

Sarcoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: NONE

Study Groups

Group I (oncology dashboard)

Radiologist records information from patient's recent scan into oncology dashboard. Patients view images of how disease may have changed over time on oncology dashboard.

Group Type: EXPERIMENTAL

Informational Intervention

Intervention Type: OTHER

View oncology dashboard

Questionnaire Administration

Intervention Type: OTHER

Ancillary studies

Group II (standard of care)

Patients receive standard of care.

Group Type: EXPERIMENTAL

Best Practice

Intervention Type: OTHER

Receive standard of care

Questionnaire Administration

Intervention Type: OTHER

Ancillary studies

Interventions

Best Practice

Receive standard of care

Intervention Type: OTHER

Informational Intervention

View oncology dashboard

Intervention Type: OTHER

Questionnaire Administration

Ancillary studies

Intervention Type: OTHER

Other Intervention Names

standard of care; standard therapy

Eligibility Criteria

Inclusion Criteria

• Patients with sarcoma on active chemotherapy/targeted therapy
• Patients must have stable to mildly progressive disease or better on baseline assessment

• Baseline measurement and follow-up measurement have to be performed on the same treatment for consistency. If patients with progressive disease are included into the study at baseline, follow-up measurement will be on a different treatment. Invariable, initiation of a new treatment, in the setting of progressive disease, lengthens oncology workflow which would affect the post measurement
• Patients must have been on the same treatment for at least 6 weeks
• Patients must have at least 3 prior imaging studies of the same body part/tracked lesion/area of interest separated by 6 weeks or more between studies
• Patients should be continuing same therapy for the next 6-8 weeks
• Patients must have plan for follow-up with imaging studies at MD Anderson Cancer Center (MDACC) while on therapy
• Patients who are receiving therapy outside of MDACC but having their follow-up imaging at MDACC are eligible
• >= 18 years of age

Exclusion Criteria

• Expected survival of less than 8 weeks
• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 4
• Non- English-speaking patients and patients with cognitive impairment who cannot complete the questionnaire

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

M.D. Anderson Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vinod Ravi

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

M D Anderson Cancer Center

Houston, Texas, United States

Countries

United States

Related Links

http://www.mdanderson.org

M D Anderson Cancer Center

Other Identifiers

NCI-2021-09453

Identifier Type: REGISTRY

Identifier Source: secondary_id

2014-0707

Identifier Type: OTHER

Identifier Source: secondary_id

2014-0707

Identifier Type: -

Identifier Source: org_study_id